CFA
IBRX icon

Carroll Financial Associates’s ImmunityBio IBRX Stock Holding History

Carroll Financial Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1K Hold
250
– – ﹤0.01% 1556
2021
Q3 		$2K Hold
250
– – ﹤0.01% 1559
2021
Q2 		$3K Sell
250
-250
-50% -$4.13K ﹤0.01% 1519
2021
Q1 		$11K Buy
+500
New +$13K ﹤0.01% 1185

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Carroll Financial Associates's IBRX Position: Q4 2021 in Review

Carroll Financial Associates held its ImmunityBio (IBRX) position steady in Q4 2021 at 250 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Carroll Financial Associates first reported a position in IBRX in Q1 2021 and has held it in 4 quarters since. The position peaked at $11K in Q1 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

  • Carroll Financial Associates held 250 shares of ImmunityBio worth $1K as of Q4 2021.
  • Carroll Financial Associates left its ImmunityBio share count unchanged in Q4 2021.
  • ImmunityBio made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1556 holding.
  • Carroll Financial Associates first reported a position in ImmunityBio in Q1 2021 and has held it in 4 quarters since.
  • Carroll Financial Associates's ImmunityBio position peaked at $11K in Q1 2021.
  • 141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.